Cyanobacteria ("blue-green algae") produce toxin with possible connection to neurodegerative disordersApril 08, 2005It is well known that a tiny number of cyanobacteria, previously known as blue-green algae, produce substances that can be toxic to both humans and animals. Now a research team from Sweden, Scotland, and the U.S. has found that a further toxin (BMAA, -methyl amino-alanine) with a possible connection to degenerative nerve diseases like ALS, Alzheimer's, and Parkinson's is produced by cyanobacteria that are widespread around the world. The findings are reported in the new issue of the Proceedings of the National Academy of Sciences, (PNAS) in the U.S. Swedish collaborators in the project are Professor Birgitta Bergman and Associate Professor Ulla Rasmussen at the Department of Botany, Stockholm University. The connection between BMAA and these disorders has been intensively studied over the years on the Pacific island of Guam, where the incidence following World War II has been 50-100 times higher than elsewhere in the world. Previously scientists thought that BMAA was produced only by cone palm trees, which are extremely common in that part of the world and have sometimes been used as food. High levels of BMAA have been found in the brains of disease victims in Guam, but since BMAA has recently been discovered in the brains of Alzheimer's patients in Canada, the hunt for the sources of the BMAA toxin has been intensified. Recently Paul Cox and his associates in the U.S. showed that BMAA is produced by a cyanobacterium that lives in the roots of the cone palm rather than in the plant itself. A research team then undertook a study of the prevalence of BMAA in cyanobacteria gathered from all over the world. It was found that more than 90 percent of all cyanobacteria studied (living freely or in symbiosis with plants) produce BMAA. Since cyanobacteria are extremely common in soil, waters, and seas and are counted among the first organisms to appear on earth, this discovery may be of both evolutionary and ecological significance. Since global warming is expected to stimulate the massive production of cyanobacteria in the oceans and the Baltic Sea, for instance, it is now essential to determine the prevalence in our environment and the possible health risks of BMAA. Scientists at the Karolinska Institutet in Stockholm have launched a research project designed to study the connection between BMAA and neurodegenerative disorders. Vetenskapsrådet (The Swedish Research Council) |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||